Robert Arthur Kratzke
University of Minnesota · 262 works · 10,538 citations · h-index 52
Top works
- RETRACTED: A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
- A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.
- Video-Assisted Thoracoscopic Surgery is More Favorable Than Thoracotomy for Resection of Clinical Stage I Non-Small Cell Lung Cancer
- Human lung carcinomas express Fas ligand.
- Rb and p16INK4a expression in resected non-small cell lung tumors.
- The pathogenesis of mesothelioma
- Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
- Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
- Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection
- Do Molecular Markers Predict Survival in Non–Small-Cell Lung Cancer?
- Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
- Immunohistochemical Analysis of the p16INK4 Cyclin-Dependent Kinase Inhibitor in Malignant Mesothelioma
- Thoracoscopic Versus Thoracotomy Approaches to Lobectomy: Differential Impairment of Cellular Immunity
- Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
- Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial
- RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma
- Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203